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Aims: To identify subgroups of patients with type 2 diabetes mellitus (T2DM) following distinct tra-
jectories of HbA1c after insulin initiation and explore underlying differences in clinical characteristics.
Materials and methods: A cohort study was conducted in patients with T2DM initiating insulin
in 2007–2013 with a follow-up of 2 to 4 years. Data were collected from the Groningen Initia-
tive to Analyze Type 2 Diabetes Treatment (GIANTT) database. The primary outcome was sub-
groups with different trajectories of HbA1c patterns after insulin initiation, as identified by
latent class growth modeling. Differences between subgroups were tested using one-way
ANOVA, Kruskal-Wallis or chi-square tests, where appropriate.
Results: From 1459 patients, three subgroups with distinct HbA1c patterns were identified.
Group 1 (8%) initially showed a moderate decrease followed by an increase in HbA1c 2 years
later, despite receiving more comedication. Group 2 (84%) showed a stable decrease. Group
3 (8%) had a high initial level of HbA1c and a rapid decline within the first year, followed by a
slow increase thereafter. Group 1 patients were on average 6–7 years younger than patients in
groups 2 and 3 and were more likely to receive sulfonylureas than Group 3 patients. Group
3 patients had a shorter diabetes duration and were less well-controlled for HbA1c, systolic
blood pressure and LDL-cholesterol at insulin initiation.
Conclusions: Most patients showed a stable HbA1c response, but one out of six patients showed
either a poor response, or a rapid initial response only after insulin initiation. Response patterns were
associated with age, diabetes duration and risk-factor controls at the time of insulin initiation.
KEYWORDS
antidiabetic drug, glycaemic control, insulin therapy, observational study, primary care, type
2 diabetes
1 | INTRODUCTION
In people with type 2 diabetes mellitus (T2DM), insulin replacement
therapy is recommended when oral therapy alone is no longer suffi-
cient to maintain glucose levels, or when oral drugs cause unwanted
side effects.1 Due to the complexity of insulin treatment and also
patients' heterogeneity, the decision to switch to insulin is made
based on patients' individual needs as well as physicians' judgements.2
Observational studies show that 15%-24% of people with T2DM will
receive insulin in the course of their treatment.3–5 Yet individual
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responses to insulin treatment vary.6 Several studies show that the
short-term glycemic response to insulin initiation is strongly depen-
dent on baseline HbA1c level, and to a lesser extent on body mass
index (BMI) and duration of diabetes.7,8
A recent Dutch study looked at HbA1c response after insulin initi-
ation over a mean follow-up period of 5.6 years and identified four
different subgroups, each following distinct trajectories of changes in
HbA1c over time.9 Patients in the subgroups were different in a num-
ber of characteristics such as age, systolic blood pressure (SBP) and
renal function, suggesting the existence of differential response phe-
notypes. However, one of the study's limitations was that the patients
were all managed in a centrally organized care system that is not rep-
resentative of routine diabetes care. Therefore, this study seeks con-
firmation in a population with T2DM which is more representative of
routine primary care practice.
The aim of this study is to identify subgroups of patients with
T2DM following distinct trajectories of HbA1c after insulin initiation.
In addition, this study aims to describe and compare clinical character-
istics of the subgroups. The findings of this study may guide individu-
alized treatment decisions regarding initiation and management of
insulin treatment in clinical practice.
2 | MATERIALS AND METHODS
2.1 | Study design and setting
A population-based study was conducted in a large dynamic cohort of
patients diagnosed with T2DM treated in Dutch routine primary care
between 2007 and 2013.
2.2 | Data source
Data were collected from the Groningen Initiative to Analyze Type 2 Dia-
betes Treatment (GIANTT) database.10 This longitudinal database con-
tains anonymized data extracted from the electronic medical records of
virtually every patient with T2DM (<1% opted out) managed by routine
general practice in the north of The Netherlands.11 Patients can enter the
cohort when they are newly diagnosed or when they move into the area
with a diagnosis of type 2 diabetes. Patients can leave the cohort when
they move out of the area, when they are no longer being treated in pri-
mary care, or when they die. The GIANTT database includes prescription
data, medical histories, results from routine laboratory tests, and physical
examinations from over 50 000 patients diagnosed with T2DM. The
GIANTT database has been extensively described and validated and has
been used previously in over 40 studies.11
2.3 | Population inclusion criteria
Patients were included if they initiated insulin treatment between
January 1, 2007 and December 31, 2013. The recommended treat-
ment target in this study period was HbA1c < 53 mmol/mol. In addi-
tion, patients needed to meet the criteria for inclusion by having:
(1) at least one HbA1c measurement taken within 365 days of
the preceding insulin initiation;
(2) insulin prescribed within 365 days before each follow-up
HbA1c measurement to ensure that insulin was not discontinued in
the follow-up period;
(3) been present in the cohort for at least two, and a maximum of
4 years, to allow for similar follow-up periods in this dynamic
cohort; and.
(4) at least four HbA1c measurements in the follow-up period.
2.4 | Baseline characteristics
Data on patient characteristics were collected at baseline (i.e. the date
of insulin initiation) on age, sex, duration of diabetes (≥2 years),
and the latest values taken from laboratory tests and physical exami-
nations within 365 days prior to insulin initiation of HbA1c, total
cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, SBP,
albuminuria (yes/no), estimated glomerular filtration rate (eGFR), BMI
and smoking status. Also included were the numbers of patients with
prescriptions for oral glucose-lowering drugs (such as metformin, sul-
fonylureas, acarbose, thiazolidines and dipeptidyl-peptidase-4-inhibi-
tors) where the duration overlapped with the date of insulin initiation,
those with histories of cardiovascular disease (ICPC-1 codes: K74,
K75, K76, K77, K83, K84, K89, K90, left ventricular hypertrophy, cor-
onary artery bypass graft, percutaneous transluminal coronary angio-
plasty), peripheral vascular disease (ICPC-1 codes: K91, K92, K99.1,
K99.6, F83, N94.2, and text-derived codes for peripheral bypass, per-
cutaneous transluminal angioplasty, diabetes nephropathy, diabetes
foot), renal disease (ICPC-1 codes: U85, U88, U90, U99.1,2,3), malig-
nancy (ICPC-1 codes: A79, B72, B73, B74, D74, D75, D76, D77,
F74.1, H75.1, K72.1, L71.1, N74, R84, R85, S77, T71, U75, U76, U77,
X75, X76, X77, Y77, Y78) and psychological conditions (ICPC-1 codes:
P77–P99). The cut-off point for diabetes duration was chosen to dis-
tinguish patients who were recently diagnosed with T2DM (diabetes
duration <2 years) from those who had diabetes for a longer period
(≥2 years). (The records of patients with a diabetes duration of
<2 years were manually checked for possible misclassification by
either the date or the diagnosis, but no obvious misclassifications
were identified.) Albuminuria was defined as being present (yes) if the
albumin-to-creatinine ratio (ACR) was ≥2.5 mg/mmol for males and ≥
3.5 mg/mmol for females. Values of eGFR were calculated from the
baseline values of serum creatinine using the CKD-EPI formula.12
2.5 | Follow-up
For each 6-months period during the follow-up the following data
were collected: the number of patients having at least one HbA1c
test, the total number of HbA1c tests which took place in the preced-
ing 90 days, the number of patients with an insulin prescription in the
preceding 90 days and the type of insulin prescribed, the number of
patients with prescriptions for oral glucose-lowering drugs (such as
metformin, sulfonylureas, acarbose, thiazolidines and dipeptidyl-pepti-
dase-4-inhibitors) where the duration overlapped each 6-months time
point, and the number of patients without any prescriptions for
glucose-lowering drugs.
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2.6 | Statistical analysis
Subgroups of patients following distinct trajectories of change in
HbA1c over time after insulin initiation were identified using latent
class growth modeling (LCGM).13 Briefly, LCGM is a technique used
to identify distinct subgroups of individuals following similar patterns
of change over time on a given variable. Although each individual has
a unique developmental course, the heterogeneity in the distribution
of individual differences by changes within the data is summarized by
a set of polynomial functions, each of which corresponds to a distinct
trajectory.
The LCGM analysis was performed in Mplus 7.4. The trajecto-
ries were modeled using a modified version of example 8.1 from
the Mplus user's guide.14 Linear, quadratic and cubic generalized
method of moments (GMM) were modeled using only HbA1c
values (no covariates) in a similar way to Mast et al.9 The model fit
indices were compared and results of the cubic models with fixed
quadratic and cubic slope variance across trajectories were pre-
sented. The default (unstructured) variance–covariance structure
was assumed to mean that each time point has its own residual
variance, and that residuals are uncorrelated across time. The graph
was plotted in Stata 14.1. The optimal number of subgroups was
determined using a stepwise approach. The number of subgroups
increased by one if all of these criteria were satisfied:
(1) the model fit (assessed by Bayesian information criterion
[BIC]) improved and the difference between the models (2 × [BIC
model 1 − BIC model 2]) was >1013;
(2) the number of patients in the newly determined subgroup is
>1% of the total population; and.
(3) the model converges (the best log likelihood has been
replicated).
The differences in the characteristics between the subgroups at
baseline were tested using one-way ANOVA for normally distributed
continuous variables, the Kruskal-Wallis test for non-normally distrib-
uted continuous variables, and the chi-square test for categorical vari-
ables. For ANOVA the pairwise comparisons were performed using
the Tukey HSD test.
2.7 | Ethics statement
In The Netherlands, according to the code of conduct for the use
of data in health research (Gedragscode Gezondheidsonderzoek,
approved in 2004 by the Dutch College for Protection of Personal
Data, taking into account Article 25 of the Dutch Act on the Pro-
tection of Personal Data), no ethics committee approval was
needed for this research using data from anonymized medical
records.
2.8 | Data-sharing and data accessibility
Clinical data from the GIANTT database cannot be made publicly
available. Other researchers may extract the data from the
GIANTT database and replicate the analysis, provided they follow
appropriate governance procedures and have received ethical
approval. Interested researchers may contact the GIANTT steering
committee (http://giantt.nl/contact.htm) to inquire about accessing
the data.
3 | RESULTS
Between January 1, 2007 and December 31, 2013, 40 131 patients
with T2DM had been on the GIANTT database for at least 1 year.
Treatment with insulin was initiated in 6592 patients. After applying
all of the inclusion and exclusion criteria, 1459 patients were selected
(Figure 1). The majority of patients (3341) were excluded because
they had received less than 2 years of follow-up after insulin initiation.
The excluded patients were slightly older, had lower SBP, higher ACR,
were less likely to be smokers, and had more comorbidities (data not
shown).
The LCGM was performed with one, two, three and four sub-
groups. The model with four subgroups did not converge. Therefore,
the optimal model describes three groups of patients with distinct pat-
terns of change in HbA1c over time. Figure 2 shows the trajectories
of HbA1c over 4 years for the three identified subgroups after insulin
initiation. HbA1c decreased in all three groups after initiation of insu-
lin, with 68%-70% not achieving the prevailing target level of
<53 mmol/mol in the study period. Group 1 consisted of poor
responders, with 119 patients showing on average a steadily increas-
ing level of HbA1c after an initial small drop (average HbA1c over the
follow-up: 67.1 mmol/mol). In Group 1, HbA1c levels increased from
an average baseline level of 60.1 to 73.0 mmol/mol at 2.5 years, after
which the number of patients included in the research substantially
decreased. Group 2 comprised stable responders, with 1227 patients
who had on average a relatively stable level of HbA1c during the
follow-up (average HbA1c over the follow-up: 57.2 mmol/mol). Group
3 consisted of initial steep responders, with 113 patients having a high
initial HbA1c level (87.9 mmol/mol) at the time of insulin initiation,
showing a rapid decline over the first year of follow-up then a small
increase during subsequent years of follow-up (average HbA1c over
the follow-up: 58.3 mmol/mol).
At baseline, the three subgroups were significantly different with
regard to age, diabetes duration, HbA1c level, the number of HbA1c
tests, total cholesterol, LDL-cholesterol, triglycerides and eGFR, and
the number of patients receiving sulfonylureas (Table 1). The poor
responders (Group 1) were significantly younger and more likely to
receive sulfonylureas than Group 3 patients. The initial rapid
responders with a high baseline level of HbA1c (Group 3) received sig-
nificantly more tests during the follow-up period, were more likely to
have a short diabetes duration (<2 years), and higher levels of total
cholesterol, LDL-cholesterol and SBP compared to groups 1 and
2. There were no differences in other oral glucose-regulating drugs at
baseline or in the type of insulin initiated.
During follow-up, 72%–86% of patients received an insulin pre-
scription within 90 days before each 6-months period, with the low-
est levels recorded for the stable responders (Group 2) (Figure 3A;
Appendix S1 [see supporting information]). For the first year and a
half the rates of insulin prescribing were slightly higher in the group of
initial rapid responders (Group 3). The prescribing of metformin
(Figure 3B, Appendix S1) and sulfonylureas (Figure 3C, Appendix S1)
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decreased in all three groups during the first 2 years after insulin initi-
ation. Patients in the group of initial rapid responders (Group 3) con-
sistently received less co-prescribing of metformin and sulfonylureas
than the other groups (Figure 3D, Appendix S1). Patients in the group
of poor responders (Group 1) received more co-prescribing of metfor-
min and sulfonylureas in the first 2 years after insulin initiation.
4 | DISCUSSION
Three distinct trajectories of HbA1c were identified in patients with
T2DM who initiated insulin in real-life practice. In the majority of
patients, HbA1c levels improved during the first year of follow-up and
remained stable during subsequent years. In contrast, there was a
smaller group (8%) consisting of younger patients with a longer diabe-
tes duration whose HbA1c levels deteriorated, despite a slight
improvement at insulin initiation. This group received more co-
prescribing of oral drug regimens including metformin and/or sulfonyl-
ureas during the follow-up period. Finally, there was another small
group (8%) of patients with a shorter diabetes duration and a higher
level of risk factors. This group had a very high HbA1c level at
baseline which declined rapidly shortly after insulin initiation, but
increased thereafter.
The findings of this study are largely in agreement with a previous
study looking at HbA1c trajectories after insulin initiation.9 Both stud-
ies clearly show the presence of a small group of poor responders, a
small group of rapid responders who had a high HbA1c level at base-
line, and a large group of patients with relatively stable HbA1c levels
during the follow-up. In addition, Mast et al.9 identified a fourth group
that consisted of patients with a very high HbA1c level at baseline
showing a slow improvement in HbA1c levels over time. The absence
of a similar group in the current study can be attributed to differences
in the studied populations or to differences in the data available for
modeling. As previously mentioned, the study by Mast et al.9 was con-
ducted in a centrally organized care system that differs from the rou-
tine primary care system in which the current study was conducted. In
this study, with multiple primary care practices there may be signifi-
cant differences in the timings of insulin initiation. In addition, the
HbA1c measurements were more unequally scheduled over time,
which may lead to differences in measurement errors in the LCGM
modeling.15
It is of note that the poor responders in Group 1 in this study
were younger and were more likely to receive sulfonylureas at base-
line and regimens including metformin and sulfonylureas during the
follow-up period. The earlier study on trajectories also reported that
poor responders were represented by a relatively younger popula-
tion.9 These findings are supported by other studies showing that
patients at younger ages have poorer glycaemic control.16,17 One of
the causes for this could be that younger patients may have a more
irregular lifestyle and consequently more problems in adhering to
treatment with insulin.18,19 The higher prevalence of patients treated
with sulfonylureas in this group may be an indicator of more severe ill-
nesses. During the follow-up period, the poor responders were trea-
ted with more intensive regimens including sulfonylureas and
metformin. This suggests that the higher HbA1c levels were not
caused by clinical inertia, but that non-adherence may be an issue
which needs to be addressed in poor responders. In addition, T2DM is
seen as a heterogeneous disorder including subgroups which can be
clinically characterized, but which also includes less well-defined phe-
notypes.20 It is possible that this group of poor responders includes
40,131 patients with type 2 diabetes present in 
GIANTT between 1.1.2007 and 31.12.2013
In 6,592 patients treatment with insulin was 
initiated
4,874 patients had at least one HbA1c measurement 
within 365 days before insulin was initiated
1,533 patients had between 2 and 4 years of 
follow up
1,459 patients had at least 4 HbA1c 
measurements 
33,539 patients did not start with 
insulin
1,718 had no HbA1c 365 days 
before insulin initiation
3,331 patients had the follow up 
less than 2 years and 10 patients
more than 4 years
74 patients did not have HbA1c 
each year in the follow-up period
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Time
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Group 3
FIGURE 2 Mean-band plot: HbA1c values against time by group.
The x-axis is divided into ten six-month intervals and the mean HbA1c
is calculated for each interval
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patients with a different disease aetiology and disease progression,
which may explain their poorer treatment responses. On the other
hand, the group of poor responders was not characterized by a
shorter diabetes duration at the time of insulin initiation.
A shorter diabetes duration was observed for the group of
patients having very high HbA1c levels at baseline with a rapid
response to insulin initiation. This indicates that within this group
there are patients who did not respond sufficiently to non-insulin
treatment. It could be that these insulin starters with such a short dia-
betes duration were misclassified, or that they could actually have
latent autoimmune diabetes in adults (LADA). Although the records of
patients with a diabetes duration of less than 2 years were manually
checked to exclude obvious misclassifications, there can be a delay
from the date of diagnosis during which patients are not yet treated.
Also, it is likely that the healthcare practitioner did not recognize
LADA in some of these patients and treated them as patients with
T2DM. The shorter diabetes duration may indicate that this group had
a larger beta-cell reserve at the time of insulin initiation. Insulin initia-
tion might have counteracted glucose toxicity and stimulated endoge-
nous insulin release, thereby explaining the strong initial response in
HbA1c levels. A group of rapid responders with high initial HbA1c
levels was also seen in the earlier study on HbA1c trajectories: Mast
et al. reported that the rapid response group showed stronger associa-
tions with mortality in comparison to the other groups.9 Further
research is needed to determine whether the groups in the current
study are also associated with different mortality and complication
(e.g. retinopathy) risks. Compared to patients in groups 1 and
2, patients in Group 3 also had higher levels of LDL-cholesterol and
SBP. The higher levels of all cardiometabolic risk factors may be an
indicator of a more severe disease or suboptimal treatment at the time
of insulin initiation, implying that more attention should be given to
improving medication treatment and adherence in this group. During
TABLE 1 Patient characteristics per group at baseline
All patients Group 1 Group 2 Group 3
Number of subjects, n 1459 119 1227 113
Follow-up in years, median (IQR) 3.4 [2.7; 3.8] 3.3 [2.7; 3.9] 3.4 [2.7; 3.8] 3.5 [2.7;3.8]
Age in years, mean (SD) 65.6 (12.4) 60.3 (12.9)a,b 66.0 (12.1)a 66.9 (13.5)b
Female, n (%) 776 (53.2) 61 (51.3) 653 (53.2) 62 (54.9)
T2DM duration >2 y, n (%) 1230 106 (89.1)a 1044 (85.1)b 80 (70.8)a,b
HbA1c in mmol/mol, mean (SD) 68.8 (17.2) 70.1 (18.9)a 66.9 (14.8)a,b 87.9 (25.9)b
Number of HbA1c tests, mean (SD) 11.8 (4.1) 11.3 (4.3)a 11.8 (4.1) 12.6 (4.1)a
Total cholesterol in mmol/L, mean (SD) 4.4 (1.1) 4.3 (0.9)a 4.4 (1.1)a,b 4.7 (1.1)b
HDL-cholesterol in mmol/L, mean (SD) 1.2 (0.3) 1.1 (0.3) 1.2 (0.3) 1.2 (0.4)
LDL-cholesterol in mmol/L, mean (SD) 2.4 (0.9) 2.4 (0.8)a 2.4 (0.9)b 2.7 (1.1)a,b
Triglycerides in mmol/L, mean (SD) 1.9 (1.1) 2.2 (1.4) 1.9 (1.1) 2.2 (1.5)
SBP in mm Hg, mean (SD) 142 (19.6) 141.4 (21.3)a 141.5 (18.8)b 147.8 (25.3)a,b
eGFR in mL/min/1.73 m2, median (IQR) 75.9 [57.3; 90.3] 85.9 [67.9; 96.8]a,b 75.0 [56.9; 89.6]a 73.3 [57.4; 87.9]b
BMI, mean (SD) 30.6 (5.7) 31.9 (8.0) 30.5 (5.6) 30.7 (6.3)
Micro/macroalbuminuria, n (%) 271 (18.6) 32 (26.9) 210 (17.1) 29 (25.7)
Smoking status, n (%) 184 (12.6) 22 (18.5) 146 (11.9) 16 (14.2)
Insulin type
Fast-acting, n (%) 42 (2.8) 4 (3.4) 34 (2.8) 4 (3.5)
Intermediate-acting, n (%) 163 (11.2) 11 (9.2) 143 (11.6) 9 (7.9)
Long-acting, n (%) 843 (57.8) 65 (54.6) 704 (57.4) 74 (65.5)
Intermediate- or long-acting
combined with fast-acting, n (%)
411 (28.2) 39 (23.8) 346 (28.2) 26 (23.0)
Metformin use, n (%) 955 (65.5) 85 (71.4) 794 (64.7) 76 (67.3)
Sulfonylureas use, n (%) 921 (63.1) 85 (71.4)a 775 (63.2) 61 (54)a
Acarbose use, n (%) 6 (0.4) 1 (0.8) 4 (0.3) 1 (0.9)
Thiazolidines, n (%) 132 (9.0) 8 (6.7) 118 (9.6) 6 (5.3)
DPP-4 inhibitors, n (%) 66 (4.5) 4 (3.4) 58 (4.7) 4 (3.5)
Other GLDs, n (%) 3 (0.2) 0 (0.0) 3 (0.2) 0 (0.0)
CV morbidity, n (%) 342 (23.4) 23 (19.3) 294 (24) 25 (22.1)
PV morbidity, n (%) 199 (13.6) 20 (16.8) 166 (13.5) 13 (11.5)
Malignancy, n (%) 143 (9.8) 8 (6.7) 128 (10.4) 7 (6.2)
Psych. conditions, n (%) 109 (7.5) 15 (12.6) 86 (7) 8 (7.1)
Abbreviations: BMI, body mass index; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; IQR, inter-
quartile range; LDL-C, low-density lipoprotein cholesterol; Psych., psychological; PV, peripheral vascular; SD, standard deviation; T2DM, type 2 diabetes
mellitus.
a,bSignificant differences (P < 0.05).
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follow-up, the patients in this group had slightly more HbA1c tests,
which is explained by closer monitoring of patients with very high ini-
tial HbA1c levels. However, on average throughout the study period,
all of the groups were regularly monitored.
There are a number of earlier studies looking at HbA1c trajecto-
ries in general.21,22 Although these studies did not look at the HbA1c
response specifically after insulin initiation, the trajectories of change
showed similar patterns. They clearly indicated the presence of a large
group of patients with stable HbA1c levels in the follow-up period, a
smaller group of patients with high HbA1c levels who appeared to
respond well after initiation or intensification of treatment, and
another small group of patients whose HbA1c levels deteriorated
slowly. This could indicate that there is a subgroup of patients with
T2DM who do not respond sufficiently to the currently available
glucose-lowering drugs which are prescribed. In the current study, the
group of poor responders did not improve, despite higher levels of
treatment regimens including metformin and/or sulfonylureas.
The rates of prescribing of insulin and other glucose-lowering
drugs varied during the follow-up. The findings show that insulin was
not continuously prescribed to all of the patients over time, which is
in accordance with earlier studies indicating that many patients have
gaps between insulin prescriptions.23,24 As expected, patients with
very high HbA1c levels at baseline were prescribed insulin more fre-
quently within the first year and a half, which corresponded with their
rapid decline in HbA1c levels.
A major strength of this study is that it was conducted in a large
cohort of patients with T2DM from a routine primary care setting in
the north of The Netherlands, and the results are therefore directly
relevant for daily clinical practice. However, there are also some limi-
tations to be considered. The population of the GIANTT cohort con-
sists mainly of individuals of western European origins, which may
influence the observed levels of HbA1c.25 Also, because this study
analyzes a real life primary-care cohort of patients, the follow-up
period was restricted to 4 years. A longer follow-up period would lead
to an increased risk of selection bias due to losses during the follow-
up. The number of patients included in the study decreased after
3 years of follow-up. This is partly because there are no data covering
the third and fourth years of follow-up for patients entering the
dynamic cohort after 2010. In addition, some patients may have left
the cohort because they died, moved out of the region, were referred
to secondary diabetes care, or moved into a care home for the elderly.
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FIGURE 3 Mean-band plot: The percentage of patients prescribed A, insulin, B, metformin, C, sulfonylureas and D, insulin only without co-
medication against time by group. The x-axis is divided into ten 6-months intervals and the mean HbA1c is calculated for each interval
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patient groups. Taking into consideration the data-driven clustering, a
prediction model was not constructed. This implies that the significant
differences observed between the groups at baseline were not
adjusted for the other characteristics. HbA1c values can be inaccurate
in patients with anaemia. There were no reliable data to confirm or
refute anaemia, but the indications are that anaemia was limited to a
specific response group. Finally, the changes in HbA1c can be driven
by factors other than insulin initiation, for instance non-adherence to
treatment and/or the dosing or intensity of medication treatment. The
feasibility of examining the prescribing of other glucose-lowering
drugs during the follow-up period was considered, but this was disre-
garded because it would not be possible to assess insulin doses or
non-adherence due to a lack of reliable data. However, patients who
discontinued insulin during the follow-up were excluded from the
cohort due to the requirement that patients needed at least one insu-
lin prescription within 365 days before each follow-up HbA1c
measurement.
In conclusion, this study confirmed the existence of distinct
groups of HbA1c trajectories in patients with T2DM initiating insulin
in routine primary care. Most patients showed a stable HbA1c
response, but one out of six patients showed either a poor response
or only a rapid initial response after insulin initiation, associated with
age, diabetes duration and risk-factor controls at the time of insulin
initiation. Poor responses occurred despite higher levels of co-
medication at insulin initiation and during follow-up. The findings
emphasize the importance of more personalized care approaches in
the process of initiation and management of insulin treatment in
patients with T2DM.
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